TLSI vs. SGHT, NYXH, INO, UTMD, ANGO, NPCE, TCMD, TMCI, DCTH, and RCEL
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Sight Sciences (SGHT), Nyxoah (NYXH), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), AngioDynamics (ANGO), NeuroPace (NPCE), Tactile Systems Technology (TCMD), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry.
Sight Sciences (NASDAQ:SGHT) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
TriSalus Life Sciences has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -67.18%. Sight Sciences' return on equity of 0.00% beat TriSalus Life Sciences' return on equity.
In the previous week, Sight Sciences had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 4 mentions for Sight Sciences and 3 mentions for TriSalus Life Sciences. Sight Sciences' average media sentiment score of 1.25 beat TriSalus Life Sciences' score of 1.03 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.
Sight Sciences has higher revenue and earnings than TriSalus Life Sciences.
Sight Sciences has a beta of 2.73, indicating that its share price is 173% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Sight Sciences currently has a consensus price target of $4.70, suggesting a potential downside of 19.52%. TriSalus Life Sciences has a consensus price target of $16.00, suggesting a potential upside of 111.36%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Sight Sciences.
Sight Sciences received 14 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Summary
TriSalus Life Sciences beats Sight Sciences on 8 of the 15 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
